Comparative Pharmacology
Head-to-head clinical analysis: DEMULEN 1 35 28 versus LO ZUMANDIMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMULEN 1 35 28 versus LO ZUMANDIMINE.
DEMULEN 1/35-28 vs LO-ZUMANDIMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial receptivity.
LO-ZUMANDIMINE is a novel small molecule inhibitor of the mitogen-activated protein kinase (MAPK) pathway. It selectively binds to and inhibits the activity of MEK1 and MEK2, thereby blocking downstream phosphorylation of ERK1/2 and inhibiting cell proliferation in tumors with activated MAPK signaling.
One tablet (contains 1 mg ethynodiol diacetate and 35 mcg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo or no tablets.
10-20 mg orally once daily, titrated to 40 mg daily based on response and tolerability.
None Documented
None Documented
Ethinyl estradiol: 17.4 ± 5.6 h (terminal); norethindrone: 10.9 ± 1.6 h (terminal); clinically, steady-state achieved within 5-7 days.
Terminal elimination half-life is 12–15 hours in adults with normal renal function. In elderly patients (>/=65 years) or those with creatinine clearance <30 mL/min, half-life extends to 20–28 hours, necessitating dose interval adjustment.
Renal 50% (metabolites), fecal 50% (biliary elimination of conjugates).
Renal excretion accounts for 60% of total clearance (30% unchanged via glomerular filtration, 30% as inactive glucuronide conjugate). Biliary/fecal elimination contributes 35% (20% as parent drug, 15% as oxidative metabolites). The remaining 5% is eliminated via sweat and expired air.
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive